Compare GNLX & CPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GNLX | CPIX |
|---|---|---|
| Founded | 2001 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 110.4M | 98.3M |
| IPO Year | 2022 | 2007 |
| Metric | GNLX | CPIX |
|---|---|---|
| Price | $2.54 | $6.58 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $17.25 | N/A |
| AVG Volume (30 Days) | ★ 307.9K | 69.5K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 9.47 | ★ 58.70 |
| EPS | ★ N/A | N/A |
| Revenue | $8,000.00 | ★ $42,010,949.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 16.75 |
| 52 Week Low | $2.29 | $1.85 |
| 52 Week High | $8.54 | $9.28 |
| Indicator | GNLX | CPIX |
|---|---|---|
| Relative Strength Index (RSI) | 42.93 | 38.10 |
| Support Level | $2.51 | $5.55 |
| Resistance Level | $2.95 | $8.27 |
| Average True Range (ATR) | 0.15 | 0.64 |
| MACD | -0.01 | -0.21 |
| Stochastic Oscillator | 28.57 | 3.17 |
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment, which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The firm promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. Its brands include Acetadote, Caldolor, Kristalose, Sancuso, Vaprisol, and Vibativ. Geographically, the company generates revenue from China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.